Table 2.
Target | Vaccine composition | Status | Dosage form | Ref |
---|---|---|---|---|
Respiratory Syncytial Virus (RSV) | Virosomes, HA, NA, RSV fusion proteins | Under GMP8 | IM | [58] |
HIV-1 | Virosomes, HA, NA, P1, gp41, TLR7/81 | New GMP | Mucose | [57] |
Hepatitis A | Virosomes, HA, NA, HAV2 | Marketed | Injection | [59] |
Influenza | Virosomes HA, NA | Marketed | Injection | [53] |
Plasmodium falciparum | Virosomes, AMA-13, CSP4, PfCyRPA5 | Phase I/II | Injection | [60,61] |
Melanoma | Virosomes, Recombinant vaccinia virus encoding five melanoma epitopes, octo-mel-rVV6 | Phase I/II | Intradermal | [62] |
SARS-CoV-2 | Virosomes HA, NA, s protein8 | Phase I/II | Injection |
Abbreviations: 1. Tool like receptor 7/8, 2. Inactivated hepatitis A virus, 3. Apical membrane antigen 1, 4. Circumsporozoite protein, 5. Plasmodium falciparum cysteine-rich protective antigens, 6. Three co-stimulatory molecules, 7. Spike protein, 8. Good manufacturing practice.